General Name:  Pegylated  New type integrated interferon  mutant injection

      Application: Chronic hepatitis B and chronic hepatitis C

      Product Features:

       1.New generation of interferon with advantages of long-lasting, high efficiency and  low toxicity
2.Long-term effect comparable with imported product with administration only once a week
3.Site specific modification technology to achieve high quality, low-cost  and better economic value
4.International advanced technology, "interferon alpha mutant and polyethylene glycol derivatives“ (PCT/CN2007 /003711) patent was authorized in the U.S., Japan, South Korea and China. Another 14 technologies  were authorized  invention patents in China

Current stage: Phase II clinical trials